<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:6pt Arial, sans-serif; }
 .font1 { font:7pt Arial, sans-serif; }
 .font2 { font:8pt Arial, sans-serif; }
 .font3 { font:9pt Arial, sans-serif; }
 .font4 { font:11pt Arial, sans-serif; }
 .font5 { font:14pt Arial, sans-serif; }
 .font6 { font:10pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5">J.P. Morgan</span></p>
<p><span class="font2" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font1" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font1" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font1" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font1" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font1" style="font-weight:bold;text-decoration:underline;"><sup>:</sup>igure 6: Highest market share gain in distribution market</span></p>
<table border="1">
<tr><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">2013</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">2014</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">2015</span></p></td><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">2013-2015 CAGR</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Sinopharm (H^g®)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">17.30%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">18.10%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">18.40%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">3.10%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">OR Ph a rm (i^^|§i5)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">9.60%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">10.20%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">10.00%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.90%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Shanghai Pharm (JtSgl?)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">8.10%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">8.30%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">8.60%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">2.60%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Jointown Pharm </span><span class="font4" style="font-variant:small-caps;">(/l^HM)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">3.50%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">3.70%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">4.00%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">7.60%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Nanjing Pharm (^^§i5)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.90%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">2.00%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">2.00%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.70%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Hua dong Phaim (^J§i5)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.70%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.70%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.80%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.70%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Renmin Tongtai (AKH#)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.30%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.20%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.70%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">48.40%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">YingtePhaim(^^g|)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.30%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.30%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">1.30%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">-1.20%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Ruikang Pharm ®f gl?)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.60%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.70%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.80%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">13.40%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Haiwang Biotech (^Hiizfe.^)</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.80%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.90%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">0.90%</span></p></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">4.20%</span></p></td></tr>
</table>
<p><span class="font0">Source: China Associalion of Pharmaceulical Commerce, JP Morgan</span></p>
<p><span class="font6" style="font-weight:bold;">Sustainable average industry growth</span></p>
<p><span class="font6">Historically, Sinopharm has maintained stable, above-industry average growth rates 3-5% faster than the overall drug distribution industry. In 1H16, the sales growth was 13.4%, above the industry sales growth of 10%, distribution industry sales growth of 12%. We expect the pharmaceutical distribution industry to continue to expand at 10%-12% in the next few years, we believe Sinopharm to achieve sales growth that is 3% faster than the overall drug distribution industry organically with its scale &amp;&nbsp;continuous market share gains.</span></p>
<p><span class="font6" style="font-weight:bold;">Optimal revenue structure with higher growth/margin of retail pharmacies</span></p>
<p><span class="font6">Sinopharm acquired the two subsidiaries from Fosun Pharma’s retail pharmacies and the transaction is expected to complete in September 2016. Sinopharm aims to build an integrated whole-retail distribution model by expanding its retail pharmacies. We believe the public hospital reform and the separation of medical sendee and drugs sales will bring significant opportunities for retail pharmacies business.</span></p>
<p><span class="font6">As of 2015, Sinopharm owes 3,080 retail pharmacies (under the &quot;Guoda’ brand name, of which 2,218 were directly operated and 952 were operated by franchisees), up from 947 in 2009. Revenue of retail pharmacies accounted for 6% of totals or Rmb9bn. As 1H16, Sinopharm owns 3,268 retail pharmacies (under the &quot;Guoda’ brand name, of which 2,309 were directly operated and 959 were operated by franchisees).</span></p>
<p><span class="font3" style="font-weight:bold;">9</span></p>
</body>
</html>